Prescription momentum swung away from the injection med after reports began to surface of a link between Byetta use and altered kidney function. Throw in concerns of pancreatic inflammation - U.S. sales for the GLP-1 agonist peaked in 2008 at $678.5 million.
The number of patients treated worldwide with Byetta dropped from 470,000 in 2007 to 440,000 in 2009, according to data obtained by Wolters Kluwer.
Launched in early 2010, Novo Nordisk’s (NVO-$90.37) GLP-1 agonist Victoza, has already passed Byetta in new patient starts …. Why? Continue Reading ….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.